Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"
- PMID: 35858159
- DOI: 10.1161/CIRCULATIONAHA.122.060526
Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"
Comment on
-
Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".Circulation. 2022 Jul 12;146(2):e5-e6. doi: 10.1161/CIRCULATIONAHA.122.060263. Epub 2022 Jul 11. Circulation. 2022. PMID: 35858158 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
